BRPI0607649A2 - prevenção de infecção por hiv - Google Patents

prevenção de infecção por hiv

Info

Publication number
BRPI0607649A2
BRPI0607649A2 BRPI0607649-1A BRPI0607649A BRPI0607649A2 BR PI0607649 A2 BRPI0607649 A2 BR PI0607649A2 BR PI0607649 A BRPI0607649 A BR PI0607649A BR PI0607649 A2 BRPI0607649 A2 BR PI0607649A2
Authority
BR
Brazil
Prior art keywords
prevention
hiv infection
hiv
formulation
long
Prior art date
Application number
BRPI0607649-1A
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Paulus Joannes Lewi
Jan Heeres
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0607649A2 publication Critical patent/BRPI0607649A2/pt
Publication of BRPI0607649B1 publication Critical patent/BRPI0607649B1/pt
Publication of BRPI0607649B8 publication Critical patent/BRPI0607649B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PREVENçãO DE INFECçãO POR HIV. A presente invenção refere-se ao uso de uma formulação parenteral compreendendo o NNRTI TMC728 para a prevenção a longo prazo de infecção por HIV em um indivíduo sob risco de ser infectado por HIV, o qual compreende a administração intermitente da dita formulação em intervalos de tempo longos.
BRPI0607649A 2005-04-04 2006-04-04 uso de uma formulação subcutânea ou intramuscular compreendendo uma quantidade eficaz de tmc278 e um veículo BRPI0607649B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102616.9 2005-04-04
EP05102616 2005-04-04
PCT/EP2006/061303 WO2006106103A2 (en) 2005-04-04 2006-04-04 Prevention of hiv- infection with tmc278

Publications (3)

Publication Number Publication Date
BRPI0607649A2 true BRPI0607649A2 (pt) 2009-09-22
BRPI0607649B1 BRPI0607649B1 (pt) 2019-08-06
BRPI0607649B8 BRPI0607649B8 (pt) 2021-05-25

Family

ID=34939113

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607649A BRPI0607649B8 (pt) 2005-04-04 2006-04-04 uso de uma formulação subcutânea ou intramuscular compreendendo uma quantidade eficaz de tmc278 e um veículo

Country Status (29)

Country Link
US (6) US20080194601A1 (pt)
EP (1) EP1881848B1 (pt)
JP (2) JP5632579B2 (pt)
KR (1) KR101360851B1 (pt)
CN (2) CN101155599A (pt)
AP (1) AP2617A (pt)
AR (1) AR053571A1 (pt)
AU (1) AU2006231585B2 (pt)
BR (1) BRPI0607649B8 (pt)
CA (1) CA2602231C (pt)
CY (1) CY1113950T1 (pt)
DK (1) DK1881848T3 (pt)
EA (1) EA011420B1 (pt)
ES (1) ES2402864T3 (pt)
HK (1) HK1198936A1 (pt)
HR (1) HRP20130296T1 (pt)
IL (1) IL184744A (pt)
ME (1) ME01517B (pt)
MX (1) MX2007012277A (pt)
MY (1) MY150091A (pt)
NZ (1) NZ556659A (pt)
PL (1) PL1881848T3 (pt)
PT (1) PT1881848E (pt)
RS (1) RS52724B (pt)
SI (1) SI1881848T1 (pt)
TW (2) TW201414495A (pt)
UA (1) UA90124C2 (pt)
WO (1) WO2006106103A2 (pt)
ZA (1) ZA200708454B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
BRPI0707179A2 (pt) 2006-01-20 2011-04-26 Tibotec Pharm Ltd tratamento de longo termo de infecção por hiv
EP2040671B1 (en) 2006-06-23 2018-01-24 Janssen Sciences Ireland UC Aqueous suspensions of tmc278
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
WO2010072844A1 (en) * 2008-12-24 2010-07-01 Tibotec Pharmaceuticals Implantable devices for treating hiv
UA112155C2 (uk) * 2009-12-21 2016-08-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Розкладаний видалюваний імплантат для безперервного вивільнення активної сполуки
DE102011082871A1 (de) * 2011-09-16 2013-03-21 Florian, Prof. Dr. Lang Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
KR20150093819A (ko) 2012-12-14 2015-08-18 글락소스미스클라인 엘엘씨 약제 조성물
US10092523B2 (en) 2014-09-26 2018-10-09 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
KR20240170635A (ko) 2023-05-24 2024-12-04 서울대학교산학협력단 R-루프의 생성을 저해시켜 hiv 감염을 억제하는 방법 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
CN1187052C (zh) 2000-03-30 2005-02-02 布里斯托尔-迈尔斯斯奎布公司 含有司他夫定(stavudine)的持续释放微球
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US20050287177A1 (en) 2002-11-08 2005-12-29 Glaxo Group Unlimited And Smithkline Beecham Corp. Pharmaceutical compositions
AU2003282883B2 (en) 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
BRPI0407329A (pt) 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv
HK1079984A1 (zh) 2003-02-21 2006-04-21 Tripep Ab 抑制hiv复制的甘氨酰胺衍生物
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
BRPI0707179A2 (pt) * 2006-01-20 2011-04-26 Tibotec Pharm Ltd tratamento de longo termo de infecção por hiv
EP2040671B1 (en) * 2006-06-23 2018-01-24 Janssen Sciences Ireland UC Aqueous suspensions of tmc278

Also Published As

Publication number Publication date
JP2008534651A (ja) 2008-08-28
AU2006231585B2 (en) 2012-02-02
IL184744A (en) 2015-05-31
AP2007004178A0 (en) 2007-10-31
CA2602231C (en) 2014-03-25
US20080194601A1 (en) 2008-08-14
CA2602231A1 (en) 2006-10-12
US20200397783A1 (en) 2020-12-24
US20220071997A1 (en) 2022-03-10
CY1113950T1 (el) 2016-07-27
AR053571A1 (es) 2007-05-09
CN101155599A (zh) 2008-04-02
US10765674B2 (en) 2020-09-08
HRP20130296T1 (hr) 2013-04-30
ZA200708454B (en) 2009-03-25
RS52724B (sr) 2013-08-30
ES2402864T3 (es) 2013-05-09
JP2013079275A (ja) 2013-05-02
ME01517B (me) 2014-04-20
PL1881848T3 (pl) 2013-06-28
BRPI0607649B8 (pt) 2021-05-25
WO2006106103A3 (en) 2007-06-07
TW200709818A (en) 2007-03-16
US20160151276A1 (en) 2016-06-02
KR101360851B1 (ko) 2014-02-11
KR20080009051A (ko) 2008-01-24
CN103860560A (zh) 2014-06-18
US20110077261A1 (en) 2011-03-31
TWI457136B (zh) 2014-10-21
HK1198936A1 (en) 2015-06-19
JP5632579B2 (ja) 2014-11-26
AU2006231585A1 (en) 2006-10-12
EP1881848B1 (en) 2013-01-16
TW201414495A (zh) 2014-04-16
MX2007012277A (es) 2007-10-17
WO2006106103A2 (en) 2006-10-12
DK1881848T3 (da) 2013-04-15
HK1117039A1 (en) 2009-01-09
NZ556659A (en) 2012-03-30
EA011420B1 (ru) 2009-02-27
UA90124C2 (ru) 2010-04-12
BRPI0607649B1 (pt) 2019-08-06
MY150091A (en) 2013-11-29
EA200702169A1 (ru) 2008-02-28
AP2617A (en) 2013-03-18
EP1881848A2 (en) 2008-01-30
PT1881848E (pt) 2013-04-15
SI1881848T1 (sl) 2013-05-31
US20160296519A1 (en) 2016-10-13
IL184744A0 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
CY1120389T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη
BRPI0607649A2 (pt) prevenção de infecção por hiv
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
BR112015014562A2 (pt) composições pesticidas e processos com estas relacionados
BRPI0816538A2 (pt) Composição polimérica, processo de preparação de uma composição polimérica, artigo à base de uma composição polimérica, uso de um artigo à base de uma composição polimérica.
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
BRPI0809366A8 (pt) polipeptídeos interligados
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
BRPI0914802A2 (pt) Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
CY1113315T1 (el) Ιμιδαζολοκαρβοξαμιδια
CY1106824T1 (el) Σταθερες ενεσιμες συνθεσεις δικλοφενακ
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
CY1114089T1 (el) Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278
NO20082097L (no) Farmasoytiske sammensetninger
EP2023900A4 (en) DRUG DISPENSING SYSTEM WITH CONTROLLED RELEASE
BRPI0822485A2 (pt) Composição farmacêutica para prevenção de disbiose associada com administração enteral de antibióticos.
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
DK1868581T3 (da) Farmaceutiske sammensætninger med forbedrede opløsningsprofiler til dårligt opløselige lægemidler
BRPI0516464A (pt) formulação farmacêutica, método para a preparação de um produto farmacêutico, e, uso de uma formulação farmacêutica
BRPI0411820B8 (pt) composição farmacêutica para administração parenteral, e seus usos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.